Mara Hutchings, NP
Primary Care · Nashville, TNNPI 1841777927
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (36.3%), other and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Angiodynamics, Inc. at 55.9% of the total. Reporting peaked in 2023 at $5,081 and has fallen 93.6% since, to $326 in 2025. Among primary care clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $59.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$8K
- Medtronic$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Johnson & Johnson$681
- Novartis$652
- AstraZeneca$291
- plus $2K from 24 others
What the payments were for
- Travel & lodging$1,76013%
- Food & beverage$5,09936%
- Education$2,40017%
- Other$4,80034%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 8 | $7,860 |
| Medtronic | 21 | $1,818 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 53 | $1,010 |
| Johnson & Johnson | 23 | $681 |
| Novartis | 39 | $652 |
| AstraZeneca | 11 | $291 |
| Boehringer Ingelheim | 12 | $234 |
| Sanofi-aventis U.S. LLC | 13 | $216 |
| Bard Peripheral Vascular, Inc. | 5 | $175 |
| Merck | 10 | $163 |
| Abiomed | 2 | $110 |
| Amgen | 6 | $102 |
| Amarin Pharma, Inc. | 4 | $80 |
| Pfizer | 4 | $79 |
| Bayer | 4 | $76 |
| Esperion Therapeutics, Inc. | 3 | $65 |
| Sanofi | 2 | $63 |
| United Therapeutics Corporation | 2 | $57 |
| Philips North America LLC | 2 | $54 |
| Actelion Pharmaceuticals US, Inc. | 1 | $38 |
| Boston Scientific | 2 | $38 |
| Cardiovascular Systems Inc. | 3 | $31 |
| Qorumpartners | 1 | $24 |
| Baxter Healthcare | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| Coala Life Inc | 1 | $23 |
| Abbott | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Smith+Nephew | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaCure 1470 Pro$7,799
- FARXIGA$125
- LifeVest$117
- Micra$107
How this compares
$14,059 in reported general payments places this provider in the 95th percentile of 189 primary care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $13,154 |
| JanuviaSitagliptin Phosphate | 23 | $12,351 |
| JardianceEmpagliflozin | 14 | $8,406 |
| FarxigaDapagliflozin Propanediol | 11 | $6,693 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,281 |
| Tamsulosin Hcl | 24 | $915 |
| Metoprolol Succinate | 47 | $550 |
| LoperamideLoperamide Hcl | 13 | $535 |
| Rosuvastatin Calcium | 25 | $522 |
| Sertraline Hcl | 32 | $354 |
| Atorvastatin Calcium | 25 | $344 |
| Potassium Chloride | 22 | $312 |
| Losartan Potassium | 32 | $289 |
| Pantoprazole Sodium | 20 | $225 |
| Amiodarone Hcl | 20 | $222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $79 | $13,15421 claims |
| MerckJanuvia | $163 | $12,35123 claims |
| Boehringer IngelheimJardiance | $234 | $8,40614 claims |
| AstraZenecaFarxiga | $291 | $6,69311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 189 primary care providers in Tennessee.
Other primary care in Nashville
- Judith CaldwellNashville$18K
- Ryan HartmanNashville$11K
- Stephanie MitchellNashville$2K
- Oumy NiangNashville$2K
- Rae TalleyNashville$1K
- Mary SullivanGermantown$115K
- Len GetzMemphis$25K
- Reena BhaktaMurfreesboro$12K
- Martha LemonsBrentwood$11K
- Abigail EubankHendersonville$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.